Why These 10 Stocks Soared Today

4. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics saw its share prices soar by 18.12 percent on Wednesday to end at $70.14 apiece as investor sentiment was buoyed by its impressive earnings performance in the first quarter of the year.

During the period, Halozyme Therapeutics, Inc. (NASDAQ:HALO) netted $118 million, higher by 53.6 percent than the $76.8 million registered in the same period last year.

Revenues increased by 35 percent to $264.86 million from $195.88 million year-on-year, thanks to higher royalty revenue and increased sales from rHuPH20, an enzyme that facilitates SC delivery of high-dose, high-volume therapeutics.

Following the strong quarter, Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its revenue outlook guidance for full-year 2025, now targeting a range of $1.2 billion to $1.28 billion, as compared with the $1.15 billion to $1.225 billion previously.

Of the total, royalty revenues are expected to reach between $750 million and $785 million, higher than the $725 million to $750 million as previously targeted.